Physician profile
Brett R Bolhofner
NPI 1134193667
$2,976,050.97
in general payments reported to CMS, 2019-2025
7 companies · $326K in 2025
The $326K reported for 2025 was more than what 99% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392K · 2020: $604K · 2021: $470K · 2022: $425K · 2023: $395K · 2024: $365K · 2025: $326K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $1.1M · Food and Beverage: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $1,086,061.50 |
| Food and Beverage | $158.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Products, INC. | $2,975,833.99 | 2019-2025 | Lcp |
| Smith+Nephew, INC. | $141.96 | 2025 | Real Intelligence, Journey II |
| Ermi LLC | $22.44 | 2019 | |
| Fidia Pharma USA INC. | $18.72 | 2019 | |
| Bioventus LLC | $16.96 | 2025 | Bonescalpel & Sonicone (O.R.) |
| Abbott Laboratories | $16.90 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,502,254.33 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Bolhofner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.